A recent meta-analysis [9] identified three clinical trials of DPP4 inhibitors in which at least one case of cholangiocarcinoma was reported [12–14]; three and four events occurred among patients receiving DPP4 inhibitors and placebo, respectively. The gene discussed is DPP4; the disease is cholangiocarcinoma.